Results 81 to 90 of about 4,927,702 (244)

Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. [PDF]

, 2008
BACKGROUND: The study describes the molecular epidemiology of Streptococcus pneumoniae causing invasive disease in Gambian children METHODS: One hundred and thirty-two S. pneumoniae isolates were recovered from children aged 2-29 months during the course
Pfluger Valentin, Greenwood, Brian M, O'Callaghan John, O'Callaghan, John, Oluwalana Claire, Okoko Brown, Pfluger, Valentin, Biney, Ekow, Oluwalana, Claire, Cutts Felicity, Cutts, Felicity, Biney Ekow, Pluschke Gerd, Awine, Tim, Okoko, Brown, Awine Tim, Vaughan Adeola, Antonio Martin, Enwere Godwin, Adegbola Richard A, Zaman, Syed Ma, Dada-Adegbola Hannah, Adegbola, Richard A, Enwere, Godwin, Vaughan, Adeola, Dada-Adegbola, Hannah, Zaman Syed MA, Greenwood Brian M, Antonio, Martin, Pluschke, Gerd   +29 more
core   +1 more source

Minimum incidence of adult invasive pneumococcal disease in Blantyre, Malawi an urban african setting: a hospital based prospective cohort study.

PLoS ONE, 2015
Invasive pneumococcal disease causes substantial morbidity and mortality in Africa. Evaluating population level indirect impact on adult disease of pneumococcal conjugate vaccine (PCV) programmes in infants requires baseline population incidence rates ...
Naor Bar-Zeev, Neema Mtunthama, Stephen B Gordon, Gershom Mwafulirwa, Neil French   +4 more
doaj   +1 more source

The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia

Journal of Biomedical Science, 2020
Background Pneumococcal conjugate vaccine (PCV) reduces both invasive pneumococcal disease (IPD) and other pneumococcal infections worldwide. We investigated the impact of stepwise implementation of childhood PCV programs on the prevalence of ...
Ching-Fen Shen, Shih-Min Wang, Hsin Chi, Yi-Chuan Huang, Li-Min Huang, Yhu-Chering Huang, Hsiao-Chuan Lin, Yu-Huai Ho, Chao A. Hsiung, Ching-Chuan Liu, Taiwan Pediatric Infectious Disease Alliance   +10 more
doaj   +1 more source

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study

ANZ Journal of Surgery, EarlyView.
Splenectomy is a safe and effective treatment option in selected patients with haematological disease, despite declining referrals over the last 27 years in the era of targeted therapies. Outcomes are favourable when performed laparoscopically and long‐term follow‐up demonstrates sustained haematologic benefit in surviving patients.
Salil Dutt Barrett, Anthony Downhill, Douglas Greer, William Stevenson, Ian Kerridge, Chris Ward, Matthew Greenwood, Naomi Mackinlay, Luke Coyle, Thomas J. Hugh   +9 more
wiley   +1 more source

Pneumococcal vaccination coverage in at-risk internists and factors influencing pneumococcal vaccination

Vaccine: X
Introduction: Pneumococcal vaccine is an effective preventive measure to reduce the burden of pneumococcal disease. This vaccine is beneficial for high-risk populations, including elderly healthcare workers and those with comorbidities.
Ceva Wicaksono, Evy Yunihastuti, Sally Aman Nasution, Lugyanti Sukrisman, Eka Ginanjar, Rudy Hidayat, Adityo Susilo, Muhadi Muhadi, Hayatun Nufus, Siprianus Ugroseno Yudho Bintoro, Hermawan Susanto, Asri Ludin Tambunan, Darmadi Darmadi, Hery Djagat Purnomo, Andi Makbul Aman, Mohammad Robikhul Ikhsan, Anggoro Budi Hartopo, Indra Wijaya, Ervita Ritonga, Ahmad Mekah, Selfie Selfie, Wira Gotera, Gede Wira Mahadita, Zen Ahmad, Radiyati Umi Partan, Brilliant V.F.S. Rhomado, Wachid Putranto, Nur Samsu, Muhammad Diah, Azzaki Abubakar, Johana Prihatini, Reinaldo Alexander, Juwanto Wakimin, Dani Rosdiana, Harnavi Harun, Akmal Mufriady Hanif, Linda Wilhelma Ancella Rotty, Cecilia Hendratta, Kuntjoro Yakti, Astried Indrasari, Erwin Erwin, Erwanto Budi Winulyo, Lukman Pura, Abimanyu Abimanyu, Djallalluddin Djallalluddin, Sutiadi Kusuma, Giri Satriya, Suharno Hakim, Andi M.H. Panjaitan, Elfiani Elfiani, Budiman Gunawan, Joko Anggoro, Arif Koswandi, Kurniakin W.S. Girsang, Andreas N.F. Lewai, Erwin A. Pangkahila, Kongko H. Nursetiyanto, Annisa Puspitasari Nachrowi, Dayang Nurbayati, Arfan Sanusi, Fahmi R. Darkuthni, Petrus Irianto, Komariatun Komariatun, Annelin Kurniati, Haeril Aswar, Nelyan H. Mokoginta, Leily D. Pawa, Edwin Ambar, Feliks Duwit, Riswan Riswan   +69 more
doaj   +1 more source

Rationale for Recommending Varicella Vaccination Into the Swedish National Immunisation Programme

Acta Paediatrica, EarlyView.
ABSTRACT Aim Under Swedish law, a vaccination may be included in the National Immunisation Programme (NIP) if it effectively prevents transmission in the population, is cost‐effective and aligns with ethical and humanitarian principles. The Public Health Agency of Sweden (PHAS) evaluated these criteria for introducing varicella vaccination. Methods The
Annika Ersson, Kari Johansen, Sören Andersson   +2 more
wiley   +1 more source

Pneumococcal Vaccine Uptake in Adults Before and After Hospitalization for Pneumococcal Infections in Hong Kong, 2015 to 2024

Vaccines
Background/Objectives: Vaccination is a key preventive measure against pneumococcal disease, but uptake rates remain low in high-risk populations. Limited information exists on pneumococcal vaccine uptake in individuals with a history of pneumococcal ...
King-Pui Florence Chan, Ting-Fung Ma, James Chung-Man Ho, Ivan Fan-Ngai Hung, Mary Sau-Man Ip, Pak-Leung Ho   +5 more
doaj   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Update on Selected Adverse Events of Concern Following Immunization With Acellular Pertussis Vaccines, a Narrative Review

Acta Paediatrica, EarlyView.
ABSTRACT Aim To provide an update paper on evidence of adverse events of concern following immunization (AEFI) with pertussis vaccines, focusing primarily on acellular (aP) vaccines. Methods Evidence was synthesised from epidemiological studies, systematic reviews over recent decades, expert interpretations in reviews from relevant research teams and ...
Lennart Nilsson, Jann Storsaeter
wiley   +1 more source